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Accumulated studies have investigated pharmacological interventions for first-episode schizophrenia (FES) pa-
tients. However, studies on subsequent treatment steps, which are essential to guide clinicians, are largely miss-
ing. This SequentialMultiple-Assignment Randomized Trials comparing Antipsychotic Treatments (SMART-CAT)
program intends to evaluate the effectiveness of commonly used antipsychotic drugs in FES patients. The major
goals of this study are to examine: 1) what would be the optimal subsequent sequential treatment if the first an-
tipsychotic drug failed; 2) whether clozapine could be used in those first-trial failed and have superior efficacy
compared to other atypical antipsychotics. In this article we will report the detail protocol of SMART-CAT.
The SMART-CAT is a randomized controlled clinical multicenter trial in which 9 institutions in China will partic-
ipate. A total of 720 FES patients will be enrolled and followed up for 12 months in this study. The trial includes
three treatment phases (each phase lasting for 8 weeks) and a naturalistic follow-up phase; participants who do
well on an assigned treatment will remain on that treatment for the duration of the 12-month treatment period,
while non-responders will move to the next phase of the study to receive a new treatment. Phase 1 is a random-
ized controlled trial; patients will be randomly assigned to one of the treatments with oral olanzapine, risperi-
done, amisulpride, aripiprazole or perphenazine. Subjects who fail to respond after 8 weeks will enter the
phase 2 randomization. Phase 2 is an equipoise-stratified randomization trial, and patients will be randomly
assigned to oral olanzapine, amisulpride or clozapine for 8 weeks. Subjects who fail to respond after phase 2
will enter an open label trial (phase 3); patients who receive clozapine in phase 2 and fail to respond will be
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assigned to an extended clozapine treatment or modified electroconvulsive therapy add-on therapy (Phase 3A).
Patients who were not assigned to clozapine in phase 2 will be assigned to treatment with clozapine or another
SGAs not previously used in phase 1 and 2 (Phase 3B). The primary outcome for the treatment phase is the treat-
ment efficacy rate, which is defined as at least 40% reduction in Positive and Negative Syndrome Scale (PANSS)
total score. We hypothesize that clozapine is more therapeutically effective than any other SGAs to patients
who failed to meet efficacy criteria in Phase 1, and earlier treatment with clozapine can improve the functional
outcomes of schizophrenia patients. As for the naturalistic follow-up phase, time to all-cause treatment failure,
marked by its discontinuation is selected as the primary outcome, since it reflects both efficacy and side effects.
The all-cause discontinuation is defined as discontinuing for any reasons, including poor efficacy, intolerance of
adverse reactions, poor compliance and other reasons.
The results of the SMART-CAT trial will provide evidence for the selection of antipsychotics in FES patients who
fail to respond to the first trial of an antipsychotic drug. It will also provide evidence for the efficacy and safety of
using clozapine in the early phase of schizophrenia treatment by comparing with other SGAs. The study is based
on the combination of sequential therapy and dynamic therapy, which can be more suitable to assess the effec-
tiveness of treatment options in the real-world clinical setting. As a result, we hope that this study can provide
guidance for an optimal treatment algorithm in first-episode schizophrenia patients.
Trial registration: ID NCT03510325 in ClinicalTrials.gov
©2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Schizophrenia is a severe mental illness that affects up to 1% of the
world population. It is characterized by a combination of positive symp-
toms, negative symptoms and cognitive impairment (Marder and
Cannon, 2019). In addition, schizophrenia is associated with social and
occupational disability, and leads to heavy societal expenditure
(Montgomery et al., 2013; Schultz and Andreasen, 1999). According to
the recent Global Burden of Diseases Study, the disability-adjusted
life-years (DALYs) of schizophrenia has increased by 17.7% since 2005
(Collaborators, 2017).
First-generation antipsychotics (FGAs) and second-generation anti-
psychotics (SGAs) are the most commonly used treatment for schizo-
phrenia (Galletly et al., 2016; Kane, 2010). Compared to the FGAs,
most SGAs have a higher affinity for the 5-HT receptor and may be
more selective on themesolimbic system; these propertiesmaybe asso-
ciated with improvement in negative symptoms and cognitive dysfunc-
tion (Zhang et al., 2013). However, some SGAs may cause significant
weight gain and cardiometabolic adverse effects (Miyamoto et al.,
2005). There have been a number of clinical trials assessing the efficacy
and safety of FGAs and SGAs in first-episode schizophrenia (FES) pa-
tients (Kahn et al., 2008; McEvoy et al., 2007; Robinson et al., 2015;
San et al., 2012; Zhang et al., 2013). The results indicated that the re-
sponse and remission rates are greatly higher in first-episode patients
than in chronic patients (Zhu et al., 2017b); however, little difference
were found among SGAs for the acute treatment of patients with first-
episode schizophrenia (Zhu et al., 2017a).
The treatment in the early phase of schizophrenia is of crucial impor-
tance, where optimal treatment could positively influence the long-
term course of the illness (Jordan et al., 2014; Lieberman et al., 2001).
However, some important questions remain unanswered. For example:
How to perform the sequential treatment if the FES patients failed the
first antipsychotic drug? And which drug will be the most optimal
choice for patients who fail their first trial? Although an FGA,
olanzapine, and risperidone are recommended by the Psychopharma-
cology Algorithm Project at the Harvard South Shore Program
(PAPHSS), the evidence for this recommendation was derived from
studies of chronic patients (Osser et al., 2013). The prospective, sequen-
tial multiple assignment randomized trial design (SMART) studies of
FES patients are largelymissing. The SMARTdesign is based on the com-
bination of sequential therapy anddynamic therapy,which ismore suit-
able to assess the effectiveness of treatment options in the real world
setting and has been widely used in mental health studies (Liu et al.,
2014). The Sequenced Treatment Alternatives to Relieve Depression
(STAR*D) trial is a multi-center, open-label SMART design trial that
has been undertaken to examine the treatment of major depressive
disorder. In the 4 levels of STAR*D, patients were randomized to various
treatment options includingmonotherapies, combinations, or augmen-
tation strategies. The results indicated that therewas nodifference in ef-
fectiveness between any treatments at any treatment level and have
shed important light on the effectiveness of current treatment strategies
for patients with depression (Rush et al., 2006a; Rush et al., 2006b;
Trivedi et al., 2006; Sinyor et al., 2010).
Another important question is about clozapine, the most commonly
used treatment for refractory schizophrenia patients (Galletly et al.,
2016; Remington et al., 2017). Recently a three-phase switching trial
was carried out in FES patients in the Optimization of Treatment and
Management of Schizophrenia in Europe (OPTiMiSE) trials (Kahn
et al., 2018; Leucht et al., 2016), which included phase 1(amisulpride
for 4 weeks in an open-label design), phase 2 (amisulpride or
olanzapine for 6 weeks in a double-blind trial) and phase 3 (clozapine
for 12 weeks in an open-label trial). The results indicated that clozapine
can be effective in early treatment (for example less than 3 months) in
nonresponding FES patients (Kahn et al., 2018). However, it is still not
clear whether clozapine could be used for first-trial failed schizophre-
nia, and prescribing clozapine earlier (such as 8 weeks) after the first
treatment failed.
This study intends to compare the effectiveness of commonly used
antipsychotic drugs in FES patients using a SMART design, which is
based on the combination of sequential therapy and dynamic therapy.
In particular, we will compare clozapine with other SGAs in the early
phase of trial. Clozapine is often recommended for treatment resistant
schizophrenia and the last option of schizophrenia treatment. Although
it is widely used in the early phase of schizophrenia treatment in China,
few studies compared the overall efficacy and safety among clozapine
and other SGAs in first-episode schizophrenia. As a result, we hope
that our study will provide guidance for the optimal treatment algo-
rithm for FES patients.
2. Rationale for trial design
The SMART-CAT trial is performed by a consortium of nine institu-
tions including seven psychiatric institutions in China. A draft study de-
sign was first developed by the Shanghai Clinical Research Center for
Mental Health (SCRC-MH) at Shanghai Mental Health Center (SMHC)
in December of 2017whichwas updated and finalized in 2018 for Insti-
tutional Review Board review and recommendations.
2.1. Our specific aims and hypotheses
● To define the appropriate treatment strategies for first-episode
schizophrenia patients who fail their first antipsychotic trial,
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especially the value of the early use of clozapine. We hypothesize
that clozapine is more effective than other SGAs for the first-trial
failed patients. Earlier treatment with clozapine can improve the
functional outcomes of schizophrenia patients.
● To determine the long-term clinical effectiveness and tolerability
of the SGAs, relative to perphenazine, in FES patients. We hypoth-
esize that SGAs are associated with better treatment compliance
and functional outcomes than perphenazine in FES patients. We
also hypothesize that different kinds of SGAs are similarly effec-
tive in treating psychotic symptoms, but have different side
effects, tolerability, compliance and functional outcomes in FES
patients.
● To verify the efficacy of clozapine in refractory, first-episode
schizophrenia. We hypothesize that clozapine is more effective
than any other SGAs in refractory schizophrenia. And MECT
add-on therapy is more effective than clozapine extended treat-
ment in clozapine treatment-resistant schizophrenia.
3. Methods
3.1. Patient sample
7 psychiatric institutions from Chinawill participate in this trial. The
study will enroll 720 patients with a first episode of schizophrenia,
schizophreniform or schizoaffective disorder according to Diagnostic
and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), and
verified with the Mini International Neuropsychiatric Interview
(M.I.N.I. 7.0) (Sheehan et al., 1998).
3.1.1. Inclusion criteria
(1) meet the DSM-5 diagnostic criteria for schizophrenia,
schizophreniform or schizoaffective disorder, (2) inpatients or outpa-
tients, (3) age between 16 and45 years old, (4) be first episode, and
the course less than 3 years, (5) drug-naïve, or taking the same antipsy-
chotic medication no longer than 2 weeks, and the cumulative antipsy-
chotic drug exposure time no more than 6 weeks, (6) the severity of
psychotic symptoms is moderate or above, which is defined as: at
least one of the following items (delusions, conceptual disorganization,
hallucinatory behavior, grandiosity, or suspiciousness/persecution)
score ≥ 4, and the PANSS total score> 70, (7) has an adequate decisional
capacity and informed consent is provided.
3.1.2. Exclusion criteria
Patients with chronic, recurrent schizophrenia or treat-resistant
schizophrenia are excluded. Patientswithmedical or psychiatric comor-
bidities and those who require concomitant other medications are ex-
cluded. Patients with contraindications to even one of the proposed
treatment arms are excluded. Patients with risks such as extreme agita-
tion, stupor or suicide are excluded. Female patients with pregnancy or
breast-feeding are also excluded.
The sample size was estimated primarily based on phase 2, but not
phase 1. The reason for focusing on sample size and power of phase 2
is that our primary objective is to define the appropriate treatment
strategies for first episode schizophrenia patients who fail the first anti-
psychotic trial, especially the value of the early use of clozapine. Accord-
ing to the previous studies, we hypothesized that the response rate of
clozapine and other SGAs in phase 2 was 52% and 37% separately
(Agid et al., 2011; Edwards et al., 2011; Kahn et al., 2018; Suzuki et al.,
2007). The α was 0.05 (one-tailed), the test efficiency (1-β) (power)
was set to 0.8,the allocation proportion of clozapine and other SGAs in
phase 2was set to be 1:2. At the same time, the response rate of first ep-
isode schizophrenia in phase 1 is 51.9% (Zhu et al., 2017b), and thewith-
drawal rate in phase 1 is about 10%. As a result, the total estimated
patient sample size is about 720.
3.1.3. Ethics and dissemination
The SMART-CAT study is conducted in accordance with the Declara-
tion of Helsinki. The study was approved by SMHC Institutional Review
Board. And written informed consent was obtained from all
participants.
3.2. Study design
Fig. 1 contains a schematic diagram of the trial design. This study is a
multi-phase RCT of antipsychotic medication treatment in schizophre-
nia patients. It includes three treatment phases (each phase lasts for
8 weeks) and a naturalistic follow-up phase. Participants who respond
well on an assigned treatmentwill remain on that treatment for the du-
ration of the 12- month treatment period. If an assigned treatment is
deemed a failure, the patients will move to the next phase of the
study to receive a new treatment. The study is single-blinded, with
the evaluators blinded to the treatment assignment; In order to repli-
cate the real-world clinical setting, the medications are open-label and
flexible, and the drug dosages are adjusted based on clinical judgment.
Phase 1 of the trial is a randomized controlled trial (RCT) for
8 weeks; patients will be randomly assigned to one of the treatments
with oral olanzapine, risperidone, amisulpride, aripiprazole or perphe-
nazine. Non-responders or patients with intolerable side effects in
phase 1 will be switch to phase 2.
Phase 2 of the trial is an equipoise-stratified randomization (ESR)
trial for 8 weeks; patients will be randomly assigned to treatment
with oral olanzapine, amisulpride or clozapine. Non-responders or pa-
tients with intolerable side effects in phase 2 will switch to phase 3.
Phase 3 of the trial is an 8-week open label trial where patients and
psychiatrists will be involved in shared decision making. If a patient re-
ceived clozapine in phase 2 failed to response, the individual will be
assigned to the clozapine extended treatment or modified electrocon-
vulsive therapy (MECT) add-on therapy (Phase 3A); alternatively,
non- clozapine users in phase 2 will be assigned to clozapine or another
SGAs not previously used in phase 1 and 2 (Phase 3B).
The follow-up phase is for patients who respond well among the
three treatment phases or non-responders experiencing the treatment
phases. Refractory patients will not be provided with study medication
and will be followed naturalistically with their choice of treatment. For
patients who relapse after meeting one of the phase response criteria
will be defined as discontinued. The interval from response to relapse
and the potential causes for recurrence will be recorded.
3.2.1. Rationale of antipsychotic medications included in phases 1 and 2
In phase 1, olanzapine, risperidone, amisulpride, aripiprazole and
perphenazine are selected. Several researches have assessed the efficacy
and safety of SGAs in FES patients (Kahn et al., 2008; McEvoy et al.,
2007; Robinson et al., 2015; San et al., 2012). A comparative review in-
dicated that there was little difference in therapeutic efficacy among
SGAs in FES patients (Salimi et al., 2009). Currently, olanzapine and ris-
peridone are the most widely used SGAs in China (Duggan et al., 2005;
Edwards, 1994). Amisulpride and aripiprazole are selected for their
unique receptor-affinity properties (El-Sayeh and Morganti, 2006;
Mota et al., 2002); Amisulpride has a selective and high affinity for do-
pamine (D3/D2) receptors (Mota et al., 2002), and aripiprazole is a par-
tial D2 receptor agonist and an 5-HT2 receptor antagonist (El-Sayeh and
Morganti, 2006). Perphenazine, a midpotency drug, was selected as the
representative of FGAs for the following reasons: first, its clinical values
in schizophrenia have been proved by the CATIE study (Lieberman et al.,
2005); second, perphenazine is inexpensive and is broadly used in
China, which is still a developing country.
In phase 2, olanzapine, amisulpride and clozapine are selected. For
the first-trial failed patients, we place greater emphasis on the efficacy
(Osser et al., 2013), while still heightening awareness of the toxicities
of some of these agents. The reason why we selected olanzapine and
amisulpride in phase 2 is that two meta-analyses showed that
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amisulpride and olanzapine were more effective than any other SGAs
(except for clozapine) in improving the overall symptoms in schizo-
phrenia patients (Huhn et al., 2019; Leucht et al., 2013).The results
from the European First-Episode Schizophrenia Trial (EUFEST) also indi-
cated that amisulpride and olanzapine were more effective than other
antipsychotics in FES patients (Boter et al., 2009; Kahn et al., 2008). As
for clozapine, some studies have revealed that clozapine is superior for
treatment-resistant schizophrenia and is the current recommendation
for treatment-resistant patients (Galletly et al., 2016; Remington et al.,
2017). Recent studies showed benefit of early clozapine treatment initi-
ation in schizophrenia patients (Agid et al., 2007; Remington et al.,
2013),and some indicated that clozapine treatment delay could lead
to negative outcomes (Shah et al., 2018; Tang et al., 2017; Ucok et al.,
2015); Moreover, the results of OPTiMiSE suggested that clozapine
could be started early in non-responding first-episode patients (Kahn
et al., 2018).
3.2.2. Patient and clinician involvement in decision making in phases 2
and 3
In phase 2, the Equipoise-Stratified Randomization is designed to
allow patients or their psychiatrists to exclude inappropriate treatment
based on previous experience or anticipated risk (Jin et al., 2013; Lavori
et al., 2001). Such design will be able to improve enrollment and reten-
tion rates. In phase 3, shared decisionmaking is essential for treatment-
refractory patients who failed twice in this trial. In addition, clozapine is
involved in phases 2 and 3. Treatment with clozapine is open-label and




Initial dosage and recommended dosing for pharmacological treat-
ments are listed in Table 1. The drug dosages will be adjusted based
on the clinicians' judgment, combining patients' therapeutic response
and potential side-effects.
The initial titration period is one week for all treatments, and later
the antipsychotics dosages can be adjusted by clinicians based on the
patients' response and side-effects. If an assigned treatment failed, the
patients will move to the next phase to receive a new treatment with
a recommended cross-titration interval for nomore than 2weeks (usu-
ally one week).
Clinicians can prescribe adjunctive and concomitantmedications ac-
cording to the patients' conditions; and clinicians are strongly
instructed to record the reasons for these prescriptions. Antipsychotics
other than the assigned study medicines are not allowed. The antipsy-
chotic cannot be discontinued or changed without considering the
treatment a failure.
3.3.2. Modified electroconvulsive therapy
Combined clozapine-MECT therapy in phase 3 is recommended as a
safe and effective treatment for clozapine-resistant schizophrenia pa-
tients (Petrides et al., 2015). Participants will sign a separate informed
consent for MECT before the standard institutional MECT procedures.
MECT will be administered three times per week for the first 2 weeks,
then twice a week for the next 2 weeks. The total treatment duration
is about one month.
3.4. Outcomes
3.4.1. Primary outcome
Subjectswill attend several follow-up visits for clinical examinations
and assessments by the following Schedule of Events (Table 2).
The primary outcome for the treatment phase is the treatment effi-
cacy rate, which is defined as a 40% reduction or more of the total
score in the Positive and Negative Syndrome Scale (PANSS) (Leucht
et al., 2005; Samara et al., 2015). This level of improvement is associated
with the level of “much improved” in the Clinical Global impressions-
Fig. 1. The SMART-CAT trial design. Responders stay on assigned medication for duration of 12-month treatment period, and non-responders move to the next phase to receive a new
treatment. RCT = randomized controlled trial, ESR = Equipoise-Stratified randomization.
Table 1
Initial dosage and recommended dosing for pharmacological treatments.
Medications Initial dosage Recommended dosing
Olanzapine 5–10 mg 5–20 mg/day
Risperidone 1–2 mg 2–6 mg/day
Amisulpride 200–400 mg 400–1200 mg/day
Aripiprazole 5–10 mg 10–30 mg/day
Perphenazine 2–4 mg 6–36 mg/day
Clozapine in phase 2 25–50 mg 200–400 mg/day
Clozapine in phase 3 25–50 mga 200–600 mg/day
a This initial dosage is for patients who first used clozapine in phase 3.
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Improvement (CGI-I) (Leucht, 2014). As for the naturalistic follow-up
phase, time to all-cause treatment failure, marked by its discontinuation
is selected as the primary outcome, for it reflects both efficacy and side
effects (Fleischhacker et al., 2005; Stroup et al., 2003), and all-cause dis-
continuation is defined as discontinuing for any reasons (including poor
efficacy, intolerance of adverse reactions, poor compliance et al.).
(Fleischhacker et al., 2005; McEvoy et al., 2007; San et al., 2012;
Stroup et al., 2003).
3.4.2. Other outcome measures
3.4.2.1. Clinical and functional assessments. In addition to PANSS (Kay
et al., 1987), Clinician-Rated Dimensions of Psychosis Symptom Severity
(CRDPS) (Barch et al., 2013; Regier et al., 2013), Calgary Depression
Scale for Schizophrenia (CDSS) (Addington et al., 1992) and Clinical
Global Impression Scale-Severity (CGI-S) (Padhi and Fineberg, 2010) are
selected for clinical assessment of patients with schizophrenia. The Uni-
versity of California, San Diego (UCSD) Performance- based Skills
Assessment-Brief (UPSA-B) (Mausbach et al., 2011)will be used to evalu-
ate the social function; The Heinirich Quality of life Scale (HRQOL)
(Heinrichs et al., 1984) is adopted for the evaluation of life quality.
Medication Satisfaction Questionnaire (MSN) (Kalali, 1999) and the Sub-
jective Well-being under Neuroleptics (SWN) (Naber et al., 2001; Naber
et al., 1994) will be used to assess whether participants were satisfied
with their assigned treatments.
3.4.2.2. Side effects, adverse events and clinical monitoring. Given the sub-
stantial clinical experience, we will use the following scales to evaluate
the potential side effects of antipsychotics. The Barnes Akathisia Scale
(BAS) (Barnes, 2003), Simpson-Angus Extrapyramidal Side Effects
Scale (SAS) (Simpson and Angus, 1970) and Abnormal Involuntary
Movement Scale (AIMS) (Listed, 1988) are used to assess extrapyrami-
dal adverse effects; the Arizona Sexual Experiences Scale (ASEX)
(McGahuey, 2000) will be employed to assess sexual dysfunction.
Each participant's vital signs, blood count, liver function, renal function,
thyroid function, serum prolactin level and QTc interval will be exam-
ined routinely. Metabolic side effects of antipsychotics, especially body
weight, waist circumstance, glucose, insulin and lipids profiles, will be
monitored regularly. The Three-Factor Eating Questionnaire (TFEQ-
R21) (Rosnah et al., 2013), Visual Analogue Scale (VAS) and Physical Ac-
tivity Evaluation will be used to assess the participants' eating and
movement status at regular intervals.
Table 2
Schedule of events.
Items V0 V1 V2 V3 V4a V5 V6a V7 V8a V9 V10 V11
Screening Baseline W2 W4 W8/M2 W12 W16/M4 W20 W24/M6 M8 M10 M12
Informed consent √
Screening, diagnosis and laboratory tests
Clinical diagnosis √ √
Physical examination √ √
Demographic information √ √
Uremic screening for drug abuses (if necessary) √
Urine pregnancy test(if necessary) √
MRI scan or CT scan(if necessary) √
Clinical monitoring and lab testsb √ √ √ √ √ √ √ √ √ √
Measures and assessment
Clinical and functional assessments
CRDPSc √ √ √ √ √ √ √ √ √ √ √
Positive and Negative Syndrome Scale (PANSS) √ √ √ √ √ √ √ √ √ √ √
Calgary Depression Scale for Schizophrenia (CDSS) √ √ √ √ √ √ √ √ √ √ √
Clinical Global Impression Scale-Severity (CGI-S) √ √ √ √ √ √ √ √ √ √ √
UPSA-Bd √ √ √ √ √
Heinirich Quality of life Scale (HRQOL) √ √ √ √ √
Medication Satisfaction Questionnaire (MSN) √ √ √ √ √
Subjective Well-being under Neuroleptics (SWN) √ √ √ √ √
Side effects and adverse events measures
The Barnes Akathisia Scale (BAS) √ √ √ √ √ √ √ √ √ √ √
Simpson-Angus Extrapyramidal Side Effects Scale (SAS) √ √ √ √ √ √ √ √ √ √ √
Abnormal Involuntary Movement Scale (AIMS) √ √ √ √ √ √ √ √ √ √ √
Arizona Sexual Experiences Scale (ASEX) √ √ √ √ √ √ √ √ √ √ √
Three Factor for Eating Question-21(TFEQ-21) √ √ √ √ √
Visual Analogue Scale (VAS) √ √ √ √ √
Physical Activity Evaluation √ √ √ √ √
Neurocognitive assessments
The MATRICS consensus cognitive battery (MCCB) √ √ √ √ √
NBSCe √ √ √ √ √
Neuroimaging(optional) √ √ √
Pharmacoeconomics assessments √ √ √ √ √ √ √
Blood samplef √ √ √
Treatment record table
Medication record table √ √ √ √ √ √ √ √ √ √ √
Adverse events (AEs) √ √ √ √ √ √ √ √ √ √ √
Study enclosure table √
a V4, V6 and V8 refer to the end of phase 1, phase 2 and phase 3 respectively; responders in phase 1, 2 or 3 will be naturalistic followed-up bimonthly for the duration of 12-month
treatment period, non-responders will move to the next phase to receive a new treatment and be followed-up monthly, whatever the response at the end of phase 3, the subjects will be
followed-up bimonthly.
b Clinicalmonitoring and lab tests include vital signs, blood count, liver function, renal function, thyroid function, serumprolactin level andQTc interval, furthermore, bodyweight,waist
circumstance, glucose, insulin and lipids profiles are also examined regularly.
c CRDPS=Clinician-Rated Dimensions of Psychosis Symptom severity.
d UPSA-B=UCSD Performance-based Skills Assessment-Brief.
e NBSC=New cognitive battery for patients with schizophrenia in China.
f Blood samples are collected for later pharmacogenomics studies.
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3.4.2.3. Neurocognitive assessments. The MATRICS consensus cognitive
battery (MCCB) has beenwidely used for cognitive function assessment
in schizophrenia patients (Kern et al., 2008; Nuechterlein et al., 2008),
and it has been validated in China (Shi et al., 2015). Recently, Shi et al.
introduced the “new” cognitive battery for patients with schizophrenia
in China (NBSC), which includes 4 tests from theMCCB and 5 new tests
(Trial making A, BACS, HVLT-R learning and recall, CPTIP, dominant
hand Grooved Pegboard, Color Trails I and II, PASAT). It was proved to
be more sensitive in detecting cognitive impairment of schizophrenia
in China (Shi et al., 2019); As a result, the 5 additional tests are also se-
lected in this study, and theNBSCwill be further verified in first-episode
patients.
3.4.2.4. Neuroimaging. About 200 participants will undergo multimodel
MRI examinaitons (structural MRI, functional MRI and Magnetic Reso-
nance Spectroscopy). Baseline and two follow-up scans (two and four
months after baseline) will be conducted. We hypothesize that thera-
peutic response in phases 1 and 2 could be identified by structural, func-
tional and metabolic differences in brain in schizophrenia patients.
3.4.2.5. Pharmacoeconomics and cost-effectiveness assessments. Tradi-
tional antipsychotic treatments were mainly evaluated by their effi-
cacy and side effects, which is important but not enough. For
example, the SGAs with high cost may not be superior to FGAs
with a low cost in the real world settings (Hastrup et al., 2013;
Park and Kuntz, 2014; Rosenheck et al., 2016). In this study, we
evaluated the direct medical costs (for example, antipsychotics
costs, medical examinations costs, health care and service costs
and adverse events costs) and indirect costs (such as traffic, nursing,
and losing of labor) of the treatments. At the same time, the quality
of life parameters are collected, which will be combined with symp-
toms to generate quality-adjusted life years (QALYs) (Nemeth et al.,
2018; Rabinowitz et al., 2013).
4. Statistical methods and analytic plan
Analyses will be conducted on the intent-to treat population and full
analysis set. The demographic data of the three phaseswill be compared
between groups by parametric test or non-parametric test according to
whether they are normally distributed.We usemeans and standard de-
viations to describe the normal distribution data,median and percentile
to describe the nonnormally distribution data. Further tests were
stopped once a comparison was found not to be significant at a two-
sided alpha level of 0.05.
4.1. Phase 1
The primary analysis will consist of a comparison of all-cause treat-
ment discontinuation rates between the perphenazine treatment group
and the pooled SGAs treatment groups (olanzapine, amisulpride,
aripiprazole, risperidone) in phase 1 from the beginning of the trial to
the following period (12 months), which will be compared between
treatment arms with a log-rank test at a two-sided alpha level of 5%.
The secondary analysis will consist of the comparison of treatment effi-
cacy among 5 antipsychotics groups. Chi-square test will be used to test
whether the response rate is significantly different among 5 groups. Be-
sides, themean score change in PANSS between groupswill be analyzed
usingKruskalWallis test. To control for type I error due tomultiple com-
parisons, a hierarchical testing procedurewill be applied for the primary
and key secondary end points.
4.2. Phase 2
The primary analysis will consist of a comparison of treatment effi-
cacy rate in clozapine treatment group and the pooled SGAs treatment
groups (olanzapine, amisulpride). Chi-square test will be used to test
whether the response rate is significantly different between clozapine
and other SGAs. Logistic regression analyses will be used to control for
covariates such as the duration of untreated psychosis (DUP) and the
severity of disease. The secondary analysis will consist of a comparison
of all-cause treatment discontinuation rates between the clozapine
group and the pooled SGAs groups (olanzapine, amisulpride) from the
beginning of phase 2 to the planned following period, which will be
compared between treatment arms with a log-rank test at a two-sided
alpha level of 5%.The DUP and the severity of disease will be corrected
with Cox regression. In the second step of the primary analysis and
the secondary analysis, the two atypical treatment groups will be
compared with clozapine group respectively. To control for type I
error due to multiple comparisons, a hierarchical testing procedure
was applied.
4.3. Phase 3
This is an exploratory phase. In Phase 3A, Chi-square test will be
used to compare the response rate between clozapine extended
group and MECT add-on therapy group. In Phase 3B, Chi-square
test will be used to compare the response rate between clozapine
group and the pooled SGAs groups (olanzapine, amisulpride, ris-
peridone, aripiprazole). And all-cause treatment discontinuation
rates will also be examined by a log-rank test at a two-sided
alpha level of 5%.
5. Summary
This article described the rationale, aims and design of the SMART-
CAT schizophrenia trial. The optimal treatment in the early phase of
schizophrenia is of crucial importance. However, some critical questions
remain unanswered and they still puzzle the clinicians. For example,
how to perform the sequential treatment after the first antipsychotic
drug fails? When should we initiate clozapine treatment? Is clozapine
more effective than other SGAs for patients who fail their first antipsy-
chotic trial? This study intends to compare the effectiveness of com-
monly used antipsychotic drugs in FES patients using a SMART design.
Based on the combination of sequential therapy and dynamic therapy,
the SMART design is more suitable to assess the effectiveness of treat-
ment options in the real-world clinical setting. We hope that our
study will provide guidance for the optimal treatment algorithm for
FES patients.
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